<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The aim of this study was to evaluate systematically the efficacy and safety of oral <z:chebi fb="0" ids="17568">uracil</z:chebi>-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHOD: Eligible studies were identified from Medline, Embase and the Cochrane Library </plain></SENT>
<SENT sid="2" pm="."><plain>The end-points included overall survival and overall <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> response rate, and toxicity including <z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">leucopenia</z:e>, febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, <z:hpo ids='HP_0010280'>stomatitis</z:hpo>/mucositis and diarrhoea </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Five randomized controlled trials were identified </plain></SENT>
<SENT sid="4" pm="."><plain>Pooled data demonstrated no difference in overall survival between the oral UFT plus LV regimen and the 5-FU bolus plus LV regimen [hazard ratio 1.013; 95% confidence interval (CI) 0.911-1.127].The fixed-effect pooled estimate for overall <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> response rate showed no significant difference between the two regimens (relative risk 0.893; 0.672-1.187) </plain></SENT>
<SENT sid="5" pm="."><plain>Grade 3-4 leucopenia [odds ratio (OR) 0.126; 955 CI 0.048-0.326], grade 1-4 leucopenia (OR 0.089; 95% CI 0.067-0.119) and grade1-4 febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (OR 0.020; 95% CI 0.004-0.102) were significantly less prominent in the oral UFT regimens </plain></SENT>
<SENT sid="6" pm="."><plain>For nonhaematological toxicities, grade 3-4 <z:hpo ids='HP_0010280'>stomatitis</z:hpo>/mucositis (OR 0.075; 95% CI 0.039-0.146), grade 3-4 infection (OR 0.484; 95% CI 0.310-0.758), grade 1-4 infection (OR 0.672; 95% CI 0.547-0.826, P &lt; 0.001), grade 1-4 diarrhoea (OR 0.743; 95% CI 0.626-0.881) were also less likely to happen in patients in the oral UFT plus LV regimen, while there was no significant difference between the two treatment regimens with respect to grade 1-4 <z:hpo ids='HP_0010280'>stomatitis</z:hpo>/mucositis (OR 0.278; 95% CI 0.053-1.456) and grade 3-4 (OR 1.174; 95% CI 0.983-1.403) diarrhoea </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Oral UFT or 5-FU bolus combined with LV results in similar overall survival and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> response rates for advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The former treatment regimen is greatly superior in terms of toxicity, especially haematological toxicity </plain></SENT>
</text></document>